Note: Descriptions are shown in the official language in which they were submitted.
COMPOSITION COMPRISING TURKEY RHINOTRACHEITIS AND INFECTIOUS
BRONCHITIS STRAIN QX ANTIGENS, WITH CpG OLIGONUCLEOTIDE
IN AN OIL EMULSION
BACKGROUND
[00011 Turkey Rhinotracheitis (TRT) is an upper respiratory tract infection of
turkeys and
chickens that is caused by pneumovirus. It is a highly contagious, acute
disease that afflicts
turkeys of all ages. The clinical symptoms of TRT infection include a marked,
frequently frothy
nasal discharge, rales, snicking, sneezing, and head shaking. Ocular discharge
or swollen
infraorbital sinuses may also be observed in infected turkeys. Antibodies to
TRT virus (TRTV)
have been detected in some chicken flocks (both broilers and
broilers/breeders) suffering from
Swollen Head Syndrome (SHS). It is postulated that TRTV plays a role in the
etiology of SHS and
related respiratory distress.
[0002] Infectious bronchitis (IB) is a coronavirus that only causes disease in
chickens, although
some other birds may be subclinically infected. Some serotypes are
geographically restricted,
but multiple serotypes commonly cocirculate in one geographic region. In
recent years, a novel
IBV genotype, the QX strain, has become increasingly common in Asia and
Europe. Morbidity is
commonly close to 100%. Chicks may cough, sneeze, and have tracheal rales for
10-14 days.
Conjunctivitis and dyspnea may be seen, and sometimes facial swelling,
particularly with
concurrent bacterial infection of the sinuses. Chicks may appear depressed and
huddle under
heat lamps. Feed consumption and weight gain are reduced. Infection with
nephropathogenic
strains can cause initial respiratory signs, then later depression, ruffled
feathers, wet droppings,
greater water intake, and death. In layers, egg production may drop by as much
as 70%, and
eggs are often misshapen, with thin, soft, rough, and/or pale shells, and can
be smaller and
have watery albumen. In most cases, egg production and egg quality return to
normal, but this
may take up to 8 weeks. In most outbreaks mortality is 5%, although mortality
rates are higher
when disease is complicated by concurrent bacterial infection.
Nephropathogenic strains can
induce interstitial nephritis with high mortality (up to 60%) in young chicks.
Infection of young
chicks may cause permanent damage to the oviduct, resulting in layers or
breeders that never
reach normal levels of production.
[0003] Known vaccine strains of IB viruses have proven insufficient to protect
against infectious
bronchitis caused by 1B-QX and 1B-QX-like viruses. See W02010017440.
1
Date Recue/Date Received 2022-09-23
[0004] Infectious bursa! disease (IBD, Gumboro) is a highly contagious
immunosuppressive
disease of chickens that is found worldwide and causes a major economic impact
on egg and
meat production. IBD Vaccines form an important part of a Gumboro control
strategy. The
choice of vaccine to be administered depends on the type of chicken being
vaccinated and the
prevailing challenge situation.
[0005] Generally, inactivated antigens have been used in poultry vaccines.
However,
manufacturing of Inactivated viruses is relatively expensive and therefore,
effective vaccines
containing lower level of the antigen would be desirable.
[0006] Another need in poultry vaccination is closely related to the cost of
vaccination itself. It
is economically advantageous to create multivalent vaccine designed to prevent
multiple
diseases. Such multivalent vaccines lower the cost of vaccine administration.
However, due to
a well-known phenomenon of antigen interference, simply mixing antigens in the
same dosage
forms often is not an effective approach to the creation of multivalent
vaccines.
[0007] Accordingly, there is a need for poultry vaccines with lowered amounts
of the antigen
and/or multivalent vaccines.
SUMMARY OF INVENTION
[0008] The instant invention provides in one aspect immunogenic composition
comprising an
antigen component and an immunologically effective amount of an adjuvant
component,
wherein the antigen component comprises at least one TRT antigen and at least
one IB antigen,
and the adjuvant component comprises an immunostimulatory oligonucleotide, oil
emulsion,
and optionally, a sterol.
[0009] In certain embodiments, the at least one TRT antigen is TRT strain K.
[0010] In certain embodiments, the at least one IB antigen is at least one of
IB D1466 and IB QX
antigen.
[0011] In certain embodiments, the immunogenic composition of the invention is
non-
liposomal and/or essentially saponin-free.
2
Date Recue/Date Received 2022-09-23
[0012] In certain embodiments, the optionally present sterol is admixed with
the
immunostimulatory oligonucleotide.
[0013] The invention also provides a vaccine comprising an antigen component
and an effective
amount of the adjuvant component, wherein the adjuvant component comprises an
immunostimulatory oligonucleotide and an oil emulsion, and wherein the antigen
component
comprises an IBD antigen.
[0014] In certain embodiments, said IBD antigen is an inactivated Lukert
strain antigen, which
may be present in the amount of 107'5- 108 TCID50.
[0015] In certain embodiments, the vaccine is a multivalent vaccine comprising
at least one of:
an antigen derived from non-Lukert strain of IBD; an Infectious bronchitis
antigen; a reovirus
antigen; a Newcastle disease antigen; a Turkey rhinotracheitis antigen.
[0016] In another aspect, the invention provides a vaccine comprising an
antigen component
and an effective amount of the adjuvant component, wherein the adjuvant
component
comprises an immunostimulatory oligonucleotide and an oil emulsion, and
wherein the antigen
component comprises: a TRT antigen; a Newcastle antigen; an Egg Drop Syndrome
(EDS)
antigen; an IBK antigen; and a Coryza antigen.
[001711n certain embodiments, the TRT antigen comprises an inactivated Turkey
Rhinotracheitis virus, the Newcastle antigen comprises an inactivated
Newcastle virus, the EDS
antigen comprises and inactivated EDS virus, the IBK antigen comprises and
inactivated IBK
virus, and the Coryza antigen comprises a mixture of Coryza M, Coryza 221 and
Coryza S
bacterins.
[0018] In certain embodiments, the TRT antigen is present in the amount of
10600 TCIDL0 to 10550
TC1050 per dose.
[0019] In certain embodiments, said oil emulsion is a W/0 emulsion.
DETAILED DESCRIPTION
[0020] Definitions:
[0021] The terms 'about' or 'approximately/ when used in connection with a
measurable
numerical variable, refer to the indicated value of the variable and to all
values of the variable
3
Date Recue/Date Received 2022-09-23
that are within the experimental error of the indicated value (e.g., within
the 95% confidence
interval for the mean) or within 10 percent of the indicated value, whichever
is greater, unless
'about' is used in reference to time intervals in weeks where "about 3 weeks,"
is 17 to 25 days,
and about 2 to about 4 weeks is 10 to 40 days.
[0022] The term 'consisting essentially of' and the like as applied to the
adjuvant formulations
of the instant invention refers to compositions which do not contain
additional adjuvanting or
immunomodulating agents in the amounts at which said agent exert measurable
adjuvanting or
immunomodulating effects.
[0023] The terms 'essentially saponin-free', 'substantially saponin-free' and
the like refer to a
composition that does not contain saponin in the amounts at which saponin
exerts measurable
adjuvanting or immunomodulating effects. In certain embodiments, essentially
saponin free
compositions contain saponin In the amount insufficient to cause systemic
immune response,
such as fever. In certain embodiments, essentially saponin-free compositions
contain no
saponin or contain saponin at or below the limit of detection.
[0024] The term 'immunostimulatory molecule' refers to a molecule that
generates an immune
response.
[0025] The term 'parenteral administration' refers to the introduction of a
substance, such as a
vaccine, into a subject's body through or by way of a route that does not
include the digestive
tract. Parenteral administration includes subcutaneous, Intramuscular,
transcutaneous,
intradermal, intraperitoneal, intraocular, and intravenous administration.
[0026] Purity percentage or "X percent pure" as applied to the
immunostimulatory
oligonudeotide preparation refers to a population of oligonucleotide molecules
comprising X%
of the named oligonucleotide (e.g., SEQ ID NO: 1, SEQ ID: NO: 5, SEQ ID NO: 8,
etc), and the
remainder (i.e., 100% minus X%) comprises shorter fragments of the named
oligonucleotide
present as impurities during the manufacturing of the named sequence. Thus, if
the sequence
is manufactured by 3'-5' sequencing, 5'-truncations would comprise the
remainder. As a non-
limiting example, a preparation of 100 j.i.g of 80% pure SEQ ID NO: 8
comprises 80 mg of SEQ ID
NO: 8 and the remaining 20 jig are shorter fragments of SEQ ID NO: 8 present
in the
preparation.
4
Date Recue/Date Received 2022-09-23
[0027] The terms 'therapeutically effective amount' immunologically effective
amount' and
'effective amount' refer to an amount of an antigen or an adjuvant or vaccine
that would
induce an immune response in a subject receiving the antigen or the adjuvant
or the vaccine
which is adequate to prevent or reduce signs or symptoms of disease, including
adverse health
effects or complications thereof, caused by infection with a pathogen, such as
a virus or a
bacterium. Humoral immunity or cell-mediated immunity or both humoral and cell-
mediated
Immunity may be induced. The immunogenicity and efficacy of a vaccine In an
animal may be
evaluated, e.g., indirectly through measurement of antibody titers, lymphocyte
proliferation
assays, or directly through monitoring signs and symptoms after challenge with
wild type strain.
The protective immunity conferred by a vaccine can be evaluated by measuring,
e.g., reduction
in clinical signs such as mortality, morbidity, temperature number, overall
physical condition,
and overall health and performance of the subject. The amount of a vaccine
that is
therapeutically effective may vary depending on the particular adjuvant used,
the particular
antigen used, or the condition of the subject, and can be determined by one
skilled in the art.
[0028] During their lives commercial laying chickens and breeder chickens are
vaccinated with a
wide variety of different vaccines. These vaccines mainly are attenuated live
vaccines. By the
time that the chickens are ready to start laying they are vaccinated with
inactivated
combination vaccines to booster immunity against the Infectious agents against
which they
already received a vaccine and to induce immunity against other agents which
can cause drops
in the egg production or other damage during the laying period. It is
important that these
vaccines are capable to induce high antibody titers and that the duration of
immunity is long,
because the vaccines should protect during the whole laying period which lasts
from an age of
approximately 20 weeks to 70 weeks. In order to achieve a long duration of
immunity it is
necessary to formulate the antigens in an adjuvant, for example a water-in-oil
(W/O) emulsion.
[0029] Thus, generally, the invention provides an immunogenic composition
comprising an
antigen component and an adjuvant component, wherein the antigen component
comprises at
least one TRT antigen and at least one IB antigen, and the adjuvant component
comprises (or,
in some embodiments, consists essentially of, or in other embodiments,
consists of) an
immunostimulatory oligonucleotide, oil emulsion, and optionally, a sterol.
Date Recue/Date Received 2022-09-23
Antigen component
[00301 Different IB QX antigens are suitable for the instant invention. In
certain embodiments
the IB OX antigen is a whole inactivated virus. In other embodiments, the
virus is a modified
live virus. In yet other embodiments, subunit vaccines may be used. For
example, proteins
present at the surface of the virus may be suitable, including, without
limitations, S protein, M
protein E-protein, or any combination thereof. In the embodiments entailing
the use of the
Inactivated whole virus, the antigen may be used in the amounts of 103 to 1010
infectious units
per dose, e.g., 104, 108, 108, 107 infectious units per dose. In certain
embodiments, the amount
of IB OX inactivated virus per dose is between about 108 and about 108
infectious units per
dose.
[00311 In further embodiments, the antigen component comprises an IBD antigen,
which, in
certain embodiments, is an inactivated Lukert IBD virus.
[00321 In certain embodiments, the amount of the inactivated Lukert IBD virus
is between 107
and 108 Tacso per dose, e.g, 1071, 10", 10", 107A, 10", 1076, 10", 1078, 10"
TCID50 per
dose.
[00331 In certain embodiments, in addition to the inactivated Lukert IBD
virus, the antigen
component of the vaccine comprises other antigens. For example, different
strains of
infectious bronchitis virus may be used, e.g., IB M41 and/or IB D1466 and/or
IB D274.
Alternatively or additionally, the vaccine of the instant invention may also
comprise TRT,
Newcastle disease (e.g., LaSota strain), EDS (egg drop syndrome), reoviruses,
and infectious
bursal disease virus antigens, avian influenza.
[00341 In other aspects, the invention provides a multivalent vaccine
comprising a TRT antigen;
a Newcastle antigen; an Egg Drop Syndrome (EDS) antigen; an IBK antigen
(Infectious bronchitis
viruses); and a Coryza antigen.
[00351 In certain embodiments of the invention, the TRT antigen is present in
the amount of
1061" TCI D50 to 106.50 Taps() per dose, e.g, 10" TCID50 or 106.10
-roD50 or 10620
TCID50 or 10630
TCID50 or 108A TCID50 or 1085 TCIDso =
[00361 Viruses used in the vaccines of this invention may be attenuated or
inactivated. The
methods for virus inactivation and attenuation are well known in the art. For
example, the
virus may be inactivated by culture passage. Methods if inactivation include,
without
6
Date Recue/Date Received 2022-09-23
limitations, exposure of the virus to an effective amount of an inactivation
chemical selected
from formalin, beta propiolactone (BPL), binary ethylenimine (BEI), or phenol.
[0037] Coryza is caused by different strains of Haemophilus paragallinarum.
Thus, in certain
embodiments, the Coryza antigen comprises one or more Haemophilus
paragollinarum strains,
e.g., strain M, strain Z, strain 221, and the like. In other embodiments, a
mixture of strains
representing serovars A, B, and C are used. Thus, strain 221 (Coryza 221) may
be used as a
Serovar A strain, strain Spross (Coryza S) may be used as a Serovar B stain,
and Strain Modesto
(Coryza M) may be used as a Serovar C strain.
[0038] A person of ordinary skill in the art may realize that the titer of a
virus may vary
depending on the methodology of virus titration, sometimes by as much as about
30%. In this
disclosure, where the doses are measured as an exponent of 10, the exponent
may vary by 0.2.
Thus, for example the titer of 1064 TCI D50 may encompass the values between
1061 TCID50 and
10640 TCID50. The same idea applies to ranges of titers. For example, the
titer of 106m ICI 1350-
1063LITCTD50 encompasses the range from 10580TCI Dso to 106'70TC1D50=
[0039] In other embodiments, other antigens may be used in addition to the
antigens recited
above, e.g., Salmonella enteritidis, Salmonella typhimurium, Mycoplasma
gallisepticum, Salmonella
gallinarum, Pasteurella multocida. Similarly to virus inactivation, bacteria
can also be inactivated
by, for example, exposure to an effective amount of an inactivation chemical
selected from
formalin, beta propiolactone (BPL), binary ethylenimine (BEI), or phenol.
Adjuvant component
[0040] Generally, the adjuvant component used in the immunogenic composition
of the
invention comprises immunostimulatory oligonucleotide, oil, and optionally,
surfactant(s). In
certain embodiments, the adjuvant component is free or essentially free of
saponins and/or
ISCOMs.
[0041] In certain embodiments, the adjuvant component consists essentially of
immunostimulatory oligonucleotide, oil, and optionally, surfactant(s). In
certain embodiments,
the adjuvant component consists of immunostimulatory oligonucleotide, oil, and
optionally,
surfactant(s).
7
Date Recue/Date Received 2022-09-23
[0042] Suitable immunostimulatory oligonucleotides include ODN (DNA-based),
ORN (RNA-
based) oligonucleotides, or chimeric ODN-ORN structures, which may have
modified backbone
including, without limitations, phosphorothioate modifications, halogenations,
alkylation (e.g.,
ethyl- or methyl- modifications), and phosphodiester modifications. In some
embodiments,
poly inosinic -cytidylic acid or derivative thereof (poly I:C) may be used.
[0043] CpG oligonucleotides are characterized by the presence of an
unmethylated CG
dinucleotlde In specific base-sequence contexts (CpG motif). (Hansel TT,
Barnes Pi (eds): New
Drugs for Asthma, Allergy and COPD. Prog Respir Res. Basel, Karger, 2001, vol
31, pp 229-232).
These CpG motifs are not seen in eukaryotic DNA,
in which CG dinucleotides are suppressed and, when present, usually
methylated, but are
present in bacterial DNA to which they confer immunostimulatory properties.
[0044] In selected embodiments, the adjuvants of the instant invention utilize
a so-called P-
class immunostimulatory oligonucleotide, more preferably, modified P- class
immunostimulatory oligonucleotides, even more preferably, E-modified P-class
oligonudeotides. P-class
immunostimulatory oligonucleotides are CpG oligonucleotides
characterized by the presence of palindromes, generally 6-20 nucleotides long.
The P-Class
oligonudeotides have the ability to spontaneously self-assemble into
concatamers either in
vitro and/or in vivo. These oligonucleotides are, in a strict sense, single-
stranded, but the
presence of palindromes allows for formation of concatamers or possibly stem-
and-loop
structures. The overall length of P- class immunostimulatory oligonucleotides
is between 19
and 100 nucleotides, e.g., 19-30 nucleotides, 30-40 nucleotides, 40-50
nucleotides, 50-60
nucleotides, 60-70 nucleotides, 70-80 nucleotides, 80-90 nucleotides, 90-100
nucleotides.
[0045] In one aspect of the invention the immunostimulatory oligonucleotide
contains a 5' TLR
activation domain and at least two palindromic regions, one palindromic region
being a 5'
palindromic region of at least 6 nucleotides in length and connected to a 3'
palindromic region
of at least 8 nucleotides in length either directly or through a spacer.
[0046] The P-class immunostimulatory oligonucleotides may be modified
according to
techniques known in the art. For example, .1-modification refers to iodo-
modified nucleotides.
E-modification refers to ethyl-modified nucleotide(s). Thus, E-
modified P-class
8
Date Recue/Date Received 2022-09-23
immunostimulatory oligonucleotides are P-dass immunostimulatory
oligonucleotides, wherein
at least one nucleotide (preferably 5' nucleotide) is ethylated. Additional
modifications include
attachment of 6-nitro-benzimidazol, 0-Methylation, modification with proynyl-
dU, inosine
modification, 2-bromovinyl attachment (preferably to uridine).
[0047] The P-class immunostimulatory oligonucleotides may also contain a
modified
internucleotide linkage including, without limitations, phosphodiesther
linkages and
phosphorothioate linkages. The oligonucleotides of the instant invention may
be synthesized
or obtained from commercial sources.
[0048] P-Class oligonucleotides and modified P-class oligonucleotides are
further disclosed in
published PCT application no. W02008/068638, published on Jun. 12, 2008.
Suitable non-
limiting examples of modified P -class immunostiumulatory oligonucleotides are
provided below
(In SEQ ID NOs 1-10, "a" refers to a phosphorothloate bond and "-" refers to a
phosphodlester
bond). In SEQ ID NOs 11-14, all bonds are phosphodiester bonds.
SEQ ID NO: 1 5' T*C-G*T*C-G*A*C-G*A*T*C-G*G*C*G*C-G*C*G*C*C*G 3'
SEQ ID NO: 2 5' T*C-G*A*C*G*T*C*G*A*T*C*G*G*C*G*C*G*C*G*C*C*G 3'
SEQ ID NO: 3 5' T*C*G*A*C*G*T*C*G*A*T*C*G*G*C*G*C*G*C*G*C*C*G*T 3'
SEQ ID NO: 4 5' JU*C-G*A*C*G*T*C*G*A*T*C*G*G*C*G*C*G*C*G*C*C*G 3'
SEQ ID NO: 5 5' JU*C-G*A*C*G*T*C*G*A*T*C*G*G*C*G*C*G*C*G*C*C* G*T 3'
SEQ ID NO: 6 5' JU*C*G*A*C*G*T*C*G*A*T*C*G*G*C*G*C*G*C*G*C*C* G*T 3'
SEQ ID NO: 7 5' EU*C-G*A*C*G*T*C*G*A*T*C*G*G*C*G*C*G*C*G*C*C*G 3'
SEQ ID NO: 8 5' JU*C-G*T*C*G*A*C*G*A*T*C*G*G*C*G*G*C*C*G*C*C* GT 3'
SEQ ID NO: 9 5' JU*C*G*T*C*G*A*C*G*A*T*C*G*G*C*G*G*C*C*G*C*C* G*T 3'
SEQ ID NO: 10 5' T*C-G*T*C-G*A*C-G*A*T*C-G*G*C*G*C_G*C*G*C*C*G 3'
SEQ ID NO: 11 5'-UUGUUGUUGUUGUUGUUGUU-3'
SEQ ID NO: 12 5'-UUAUUAUUAUUAUUAUUAUU-3'
SEQ ID NO: 13 5'-AAACGCUCAGCCAAAGCAG-3'
SEQ ID NO: 14 5'-dTdCdGdTdCdGdTdTdIdTrGrUrUrGrUrGrUdTdIdTdT-3'
[0049] The immunostimulatory oligonucleotides of the instant invention may be
chemically
synthesized. Further, the immunostimulatory oligonucleotides may be used at
about 60%
9
Date Recue/Date Received 2022-09-23
purity (homogeneity) or greater (e.g., about 65%, about 70%, about 75%, about
80%, about
85%, about 90%, about 95%, about 98%, or 100% purity)
[00501 The amount of P-class immunostimulatory oligonucleotide for use in the
adjuvant
compositions depends upon the nature of the P-class immunostimulatory
oligonucleotide used
and the intended species.
[00511 Sterols share a common chemical core, which is a steroid ring
structure[s], having a
hydroxyl (OH) group, usually attached to carbon-3. The hydrocarbon chain of
the fatty-acid
substituent varies in length, usually from 16 to 20 carbon atoms, and can be
saturated or
unsaturated. Sterols commonly contain one or more double bonds in the ring
structure and also
a variety of substituents attached to the rings. Sterols and their fatty-acid
esters are essentially
water insoluble. In view of these chemical similarities, it is thus likely
that the sterols sharing
this chemical core would have similar properties when used in the vaccine
compositions of the
instant invention. Sterols are well known in the art and can be purchased
commercially. For
example cholesterol is disdosed in the Merck Index, 12th Ed., p. 369. Suitable
sterols include,
without limitations, 13-sitosterol, stigmasterol, ergosterol, ergocalciferol,
cholesterol, and
derivatives thereof such as, for example DC-
Cholesterol (3f3-(N-
(Dimethylaminoethane)carbamoyllcholesterol).
[00521 Multiple oils and combinations thereof are suitable for use of the
instant invention.
These oils include, without limitations, animal oils, vegetable oils, as well
as non-metabolizable
oils. Non-limiting examples of vegetable oils suitable in the instant
invention are corn oil,
peanut oil, soybean oil, coconut oil, olive oil, and phytosqualane. Non-
limiting example of
animal oils is squalane. Suitable non-limiting examples of non-metabolizable
oils include light
mineral oil, straight chained or branched saturated oils, ramified oils, and
the like.
[00531 In a set of embodiments, the oil used in the adjuvant formulations of
the instant
invention is a light mineral oil. As used herein, the term "mineral oil"
refers to a mixture of
liquid hydrocarbons obtained from petrolatum via a distillation technique. The
term Is
synonymous with "liquefied paraffin", "liquid petrolatum" and "white mineral
oil." The term is
also intended to include "light mineral oil," i.e., oil which is similarly
obtained by distillation of
petrolatum, but which has a slightly lower specific gravity than white mineral
oil. See, e.g.,
Date Recue/Date Received 2022-09-23
Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pa.: Mack
Publishing Company,
1990, at pages 788 and 1323). Mineral oil can be obtained from various
commercial sources, for
example, J. T. Baker (Phillipsburg, Pa.), USB Corporation (Cleveland, Ohio).
Preferred mineral oil
is light mineral oil commercially available under the name DRAKEOL6. In
another embodiment,
the suitable oil comprises mineral oil MARCOLT" 52. MARCOLT" 52 is a purified
mixture of liquid
saturated hydrocarbons. It is a crystal clear, water-white product that
contains no toxic
Impurities. It Is obtained from petroleum by vacuum distillation with
subsequent refining
stages including an ultimate purification by catalytic hydrogenation.
[0054] Emulsifiers suitable for use in the present emulsions include natural
biologically
compatible emulsifiers and non-natural synthetic surfactants. Biologically
compatible
emulsifiers include phospholipid compounds or a mixture of phospholipids.
Preferred
phospholipids are phosphatidylcholines (lecithin), such as soy or egg
lecithin. Lecithin can be
obtained as a mixture of phosphatides and triglycerides by water-washing crude
vegetable oils,
and separating and drying the resulting hydrated gums. A refined product can
be obtained by
fractionating the mixture for acetone insoluble phospholipids and glycolipids
remaining after
removal of the triglycerides and vegetable oil by acetone washing.
Alternatively, lecithin can be
obtained from various commercial sources. Other suitable phospholipids include
phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, phosphatidic
acid, cardiolipin,
phosphatidylethanolamine, lysophosphatidylcholine,
lysophosphatidylserine,
lysophosphatidylinositol, and lysophosphatidylethanolamine. The phospholipids
may be
isolated from natural sources or conventionally synthesized.
[0055] In additional embodiments, the emulsifiers used herein do not include
lecithin, or use
lecithin in an amount which is not immunologically effective.
[0056] Non-natural, synthetic emulsifiers suitable for use in the adjuvant
formulations of the
present invention include sorbitan-based non-ionic surfactants, e.g. fatty-
acid-substituted
sorbitan surfactants (commercially available under the name SPANS or ARLACEL
), fatty acid
esters of polyethoxylated sorbitol (TWEENfl, polyethylene glycol esters of
fatty acids from
sources such as castor oil (EMULFOR); polyethoxylated fatty acid (e.g.,
stearic acid available
under the name SIMUL5OL6 M-53), polyethoxylated isooctylphenol/formaldehyde
polymer
11
Date Recue/Date Received 2022-09-23
(TYLOXAPOL), polyoxyethylene fatty alcohol ethers (BRIr); polyoxyethylene
nonphenyl ethers
(TRITON* N), polyoxyethylene isooctylphenyl ethers (TRITON X). Preferred
synthetic
surfactants are the surfactants available under the name SPAN* and TWEEN*,
such as TWEEN6-
80 (Polyoxyethylene (20) sorbitan monooleate) and ARLACELTM 83V (Sorbitan
Sesquioleate)).
[0057] Generally speaking, the emulsifier(s) may be present in the vaccine
composition in an
amount of 0.01% to 40% by volume, preferably, 0.1% to 15%, more preferably 2%
to 10%.
[0058] In a subset of embodiments, the volume percentage of the oil and the
oil-soluble
emulsifier together is at least 50%, e.g., 50% to 95% by volume; preferably,
in an amount of
greater than 50% to 85%; more preferably, in an amount from 50% to 60%, and
more
preferably in the amount of 55-65% v/v of the vaccine composition. Thus, for
example and
without limitations, the oil may be present in the amount of 45% and the lipid
soluble
emulsifier would be present in the amount of greater than 5% v/v. Thus, the
volume
percentage of the oil and the oil-soluble emulsifier together would be at
least 50%.
[0059] In yet another subset, applicable to all vaccines of the invention,
volume percentage of
the oil is over 40%, e.g., 40% to 90% by volume; 40% to 85%; 43% to 60%, 44-
50% v/v of the
vaccine composition. In certain embodiments, the emulsions contain at least
60% v/v oil phase
and 40% v/v aqueous phase.
[0060] Sometimes, it is impossible or impracticable to concentrate the
antigen, particularly in
scaled up commercial applications, and low-concentrations of antigen solutions
have to be
used. Thus in some embodiments, the vaccine compositions of the instant
invention comprise
the adjuvant formulations as described above, wherein the content of the oily
phase in these
adjuvant formulations is diluted and wherein the vaccine composition is a
water-in-oil
emulsion.
[0061] In practice, it is possible to create a water-in-oil emulsion wherein
the oily phase is less
than 50% v/v.
[0062] Briefly, first, the adjuvant formulation of the instant invention is
prepared as described
above. In said adjuvant formulation, the oily phase comprises over 50% v/v of
the adjuvant
formulation. The amounts of ingredients other than the oil and the
emulsifier(s) are scaled up
respectively, based on the final target concentration and desired dilution.
For example, if one
12
Date Recue/Date Received 2022-09-23
aims to prepare a vaccine composition where the adjuvant formulation comprises
80% v/v, the
amounts of ingredients other than the oil are scaled up by the factor of 1.25
(1/0.8). The
amounts of emulsifiers, if any (e.g., TWEEN680 and/or SPAN680) do not
necessarily need to be
scaled up, but preferably, the volume ratio between the oil and the
emulsifier(s) is kept the
same in the adjuvant formulation and in the final vaccine composition.
[0063] Antigen solution is then added to the adjuvant formulation.
[0064] Water-In-oil emulsion's Integrity can be maintained as long as the
dispersed spherical
water droplets are not present in a more concentrated form than the maximum
packing
fraction for random packing of monodisperse droplets, i.e.: 0.64. See Tadros,
Emulsion
Formation, Stability and Rheology, 1" ed. 2013, Wiley-VCH GmbH & Co KGaA. As
long as the
total volume fraction occupied by the aqueous droplets does not exceed 0.64,
i.e.: 64% v/v.
Conversely, this implies that the oily phase should not drop below 36% v/v.
[0065] In some embodiments suitable, one dose of the adjuvant would contain
between about
0.1 and about 20 lig (e.g., 1-20 rig, or 5-15 pg or 8-12 lig or 10 lig) of
immunostimulatory
oligonudeotide, up to about 50 ug (e.g., 0.5-20 jig, or 1-10 jig) of the
sterol such as cholesterol.
[0066] In certain embodiments, the adjuvant component is prepared as follows:
a) Sorbitan Sesquioleate, and cholesterol, if any, are dissolved in light
mineral oil. The
resulting oil solution is sterile filtered;
b) The immunostimulatory oligonucleotide and Polyoxyethylene (20) sorbitan
monooleate are dissolved in aqueous phase, thus forming the aqueous solution;
c) The aqueous solution is added to the oil solution under continuous
homogenization.
[0067] The immunogenic composition of the instant invention may be prepared by
adding the
antigen component to the aqueous phase followed by combining the aqueous phase
with the
oil phase. In other embodiments, the antigen component may be added to the
adjuvant
component after the adjuvant component is prepared.
[0068] The immunogenic composition may further comprise a pharmaceutically
acceptable
carrier. As used herein, "a pharmaceutically-acceptable carrier" includes any
and all solvents,
dispersion media, coatings, adjuvants, stabilizing agents, diluents,
preservatives, antibacterial
and antifungal agents, isotonic agents, adsorption delaying agents, and the
like. The carrier(s)
13
Date Recue/Date Received 2022-09-23
must be "acceptable" in the sense of being compatible with the other
components of the
compositions and not deleterious to the subject. Typically, the carriers will
be sterile and
pyrogen-free, and selected based on the mode of administration to be used. It
is well known by
those skilled in the art that the preferred formulations for the
pharmaceutically acceptable
carrier which comprise the compositions are those pharmaceutical carriers
approved in the
applicable regulations promulgated by the United States (US) Department of
Agriculture or US
Food and Drug Administration, or equivalent government agency In a non-US
country.
Therefore, the pharmaceutically accepted carrier for commercial production of
the
compositions is a carrier that is already approved or will be approved by the
appropriate
government agency in the US or foreign country.
[0069] Other components of the compositions can include pharmaceutically
acceptable
excipients, such as carriers, solvents, and diluents, isotonic agents,
buffering agents, stabilizers,
preservatives, vaso-constrictive agents, antibacterial agents, antifungal
agents, and the like.
Typical carriers, solvents, and diluents include water, saline, dextrose,
ethanol, glycerol, oil, and
the like. Representative isotonic agents include sodium chloride, dextrose,
mannitol, sorbitol,
lactose, and the like. Useful stabilizers include gelatin, albumin, and the
like.
Administration of the Vaccine
[0070] Generally, the vaccines of the instant invention may be administered
via multiple
routes. Such routes are known to persons of ordinary skill in the art and
include, without
limitations intramuscular and subcutaneous injections.
[0071] In certain embodiments, the vaccines are administered at about 3-7
weeks (e.g., about
4-6 weeks) before the expected lay. This regimen ensures that the immunity to
IB QX is
developed by the time of lay and persists throughout the laying period of the
vaccinated hens.
[0072] In additional embodiments, the vaccine of the instant invention is
administered as a
booster vaccine, to hens which have been primed. Multiple IB primers are known
in the art.
For example, POULVAC3 IB Primer comprises a freeze-dried, Massachusetts type,
live Infectious
Bronchitis virus. NobIIis IB H120 is a live freeze-dried vaccine indicated for
use as a primary
vaccination of fowls against Infectious Bronchitis. This vaccine contains
strain H120 type
Massachusetts. Other IB primers may also be used with the vaccine of the
instant invention.
14
Date Recue/Date Received 2022-09-23
[00731 The invention will further be described in the following non-limiting
examples.
EXAMPLES
Example 1. Vaccine Preparation
[00741 Exemplary water-in-oil emulsion is provided in Table 1. The antigens
are diluted in the
water phase to which also CpG is added. The water phase comprises antigens,
CpG and
Thimerosal. It is mixed with the oil phase. After thorough mixing, a stable
W/O emulsion is
formed.
Table 1. Composition of a W/O emulsion.
Aq. Phase (40%): 80 mL
Components Stock JUNNWINERMin Quantity (mL)
Tween80 100% purity 0.004 mUdose 1.6
Thimerosal 1% 100% purity 0.005 mUdose 2.0
CpG (SEQ ID NO: 10 pg/close
8, 65% purity) 20000 pg/mL 0.2
Saline Solution + N/A add 0,5mL
antigens N/A 76.2
Sub-total 80.0
Oil Phase (60%) 120 mL
Components Stock Target Quantity (g)
AriaceIrm 83V 100% purity 0.239 g/dose 95.6
MarcolTM 52 100% purity 0.023 g/dose 9.2
Sub-total 104.8
Final emulsion
Components Stock Target, v/v Volume (mL)
Aq. Phase (40%) 100% purity 40% 80.0
Oil Phase (60%) 100% purity 60% 120.0
Total
Volume 200.0 mL
Example 2. Potency assays for IB or TRT
[00751 The inventors produced W/0 emulsions containing inactivated IB M41
antigen (1072
ElDso before inactivation per dose) or inactivated TRT antigen (1053 TCIDso
before inactivation
per dose). These emulsions contained different quantities of CpG or no CpG
(SEQ ID NO: 8, 65%
Date Recue/Date Received 2022-09-23
purity). The emulsions were tested in a potency test in chickens. The chickens
were vaccinated
at an age of 4 weeks. At 5 weeks after vaccination blood samples were
collected and tested for
antibody titers against the antigens by ELISA.
[0076] Antibody titres against turkey rhinotracheitis (TRT) virus were
determined using an
enzyme-linked immunosorbent assay (ELBA) in which the antigen was coated to
the wells of 96
wells micro [LISA plates. After coating standard negative and standard
positive sera were added
to the wells and the sera to be tested. All sera were tested In duplicate. As
control all sera were
tested also in duplicate in wells without antigen. Unbound antibodies were
removed and the
reactivity of the antibodies to the antigen was visualized by adding
antibodies against the serum
antibodies to which peroxidase had been conjugated. After removal of unbound
conjugated
antibodies, the peroxidase substrate ortho phenylene diamino + H202 was added.
The presence
of peroxidase was demonstrated by the development of a color reaction.
[00771 The results of the potency test of the TRT antigen are summarized in
Table 2. In general
antibody titers were satisfactory and there were no non-responders in any of
the groups. There
was a positive effect of CpG on the antibody titers. Best results were
obtained with 10 lig CpG
per dose, but also 1 ug CpG per dose had a positive effect.
Table 2. Antibody titers in blood samples from chickens vaccinated 5 weeks
earlier at an age of 4 weeks
with inactivated TRT antigen formulated in a W/O emulsion containing different
quantities of CpG.
TRT log2 antibody titers by ELISA
CpG/dose 01.1g 1 ps 10 ug
10.53 12.30 16.03
11.38 14.99 16.93
7.78 15.27 12.77
17.25 13.16 15.64
Individual titers
11.47 15.71 15.20
expressed as
10.68 12.37 15.31
log2 titers
14.03 12.40 17.10
12.06 13.04 16.16
15.21 15.74 13.92
12.28 15.84
Average 12.27 13.89 15.49
16
Date Recue/Date Received 2022-09-23
[00781 Also a positive effect of CpG was determined on the antibody response
against IB M41,
see Table 3. A dose of 1 1.tg CpG per dose already was sufficient to stimulate
the antibody
response substantially. Without CpG, 7 out of 15 chickens had an antibody
response below the
threshold of 2.60, whereas all chickens responded when 1 pg CpG per dose was
tested. A
further increase was obtained with 10 pg CpG per dose.
Table 3. Antibody titers in blood samples from chickens vaccinated 5 weeks
earlier at an age of 4 weeks
with inactivated IB M41 antigen formulated in a W/O emulsion containing
different quantities of CpG.
18 antibody titers by ELISA
0/W + 1 p.g 0/W + 10 pg
Treatment group 0/W CpG/dose CpG/dose
3,65 4,06 3,79
2,08 3,12 3,32
2,49 3,97 3,89
2,84 2,80 3,85
0,00 3,14 3,76
3,19 2,62 3,59
Individual titers 0,00 3,54 3,59
expressed as 0,00 3,18 3,17
LogioTiter 2,42 3,36 3,12
2,48 2,99 3,42
3,33 3,42 3,94
2,74 3,73 3,76
2,86 3,18 4,11
3,23 3,91 3,86
2,83 4,13
Average 2,28 3,36 3,69
*Titers higher than 396 (Log1oTiter=2.60) are considered positive by the
kit.
Example 3. Potency assays for IL ND, EDS
[00791 Groups of 10 SPF chickens were vaccinated with 0.5 ml per dose
intramuscularly at an
age of 4 weeks. Blood samples for serological testing were collected at 5
weeks after
vaccination. For measuring antibody titres against IB, ND and EDS, an ELISA
(idexx FlockCheck
IBV antibody kit; !dem, Maine, USA), a hemagglutination inhibition test and an
ELISA (Idexx
FlockCheck NCD antibody kit; Idexx, Maine, USA), respectively were used.
17
Date Recue/Date Received 2022-09-23
[00801 The vaccines contained:
IB M41: 106'9 ElDso/dose,
Newcastle disease (ND): E IDso/d ose,
Egg-Drop Syndrome (EDS): 256 HAu/dose,
in water in oil emulsions containing different quantities of CpG.
[0081] Groups of 10 SPF chickens were vaccinated with 0.5 ml per dose
intramuscularly at an
age of 4 weeks. Blood samples for serological testing were collected at 5
weeks after
vaccination. For measuring antibody titres against IB, ND and EDS, an ELISA
(Idexx FlockCheck
IBV antibody kit; idexx, Maine, USA), a hemaggiutination Inhibition test and
an ELISA (Idexx
FlockCheck NCD antibody kit; Idexx, Maine, USA), respectively were used.
[00821 The results for I B, ND, and EDS are shown in Tables 4-6, respectively
Table 4. [LISA I B antibody titers days after vaccination
Vaccine batch N Geometric mean 2Iog No. of responders
Not vaccinated 10 3.0 0(0%)
No CpG 10 7.7 A- 4(40%)
pg CpG/close I 10 9.9 a 8(80%)
2.5 pg CpG/dose 10 7.3 A 3(30%)
Table 5. ELISA NCD antibody titers 35 days after vaccination
Vaccine batch N Geometric mean No. of responders
Not vaccinated 10 34 0(0%)
No CpG 10 12532 A 10(100%)
5 lig CpG/dose 10 18421 5 10(100%)
2.5 pg CpG/dose 10 15689 10(100%)
Table 6. HI antibody titers to EDS 35 days after vaccination
Vaccine batch N Geometric mean No. of responders
Not vaccinated 10 0 0(0%)
No CpG 10 7.7 A 10(100%)
5 pg CpG/dose 10 8.4 A 10(100%)
2.5 pg CpG/dose 10 7.8 A (100%)
= Different letters in superscript mean that the differences are
statistically significant.
18
Date Recue/Date Received 2022-09-23
[0083] Results and conclusions
[0084] For IB M41 and ND there are significant differences between
formulations without CpG
and formulation with 5 pg CpG per dose. For ND 2.5 pg CpG per dose also
improved antibody
titres significantly. For EDS there were no significant differences between
formulations without
CpG and formulations with CpG, but numerically 5 pg CpG per dose was better
than no CpG.
[0085] CpG has a stimulating effect on the antibody responses of IB M41, ND
and EDS if added
in a quantity of 5 i.tg per dose. The effect of 2.5 pg CpG per dose is
limited.
Example 4. Efficacv test
[0086] Combination vaccines were produced containing different quantities of
inactivated IB
OX, inactivated IB D1466 and inactivated TRT antigens in W/0 emulsion
containing 10 lag per
dose of CpG. These emulsions were used to vaccinate SPF layers at an age of 14
weeks. Half of
the different vaccine groups had been vaccinated at an age of 10 weeks with
live 1B vaccines. At
an age of 26 weeks the chickens were challenged with virulent OX-like IB virus
or virulent IB
D1466 virus. Between 2 weeks before challenge and 4 weeks after challenge egg
production
was measured. Furthermore, antibody titers were measured at 7 weeks after
vaccination with a
serum neutralization test.
[0087] As can be seen In the data presented in Table 4 after live priming a
clear antibody
response could be detected by ELISA. After vaccination with the inactivated
vaccines also
antibody titers against IB were determined by SN tests. The SN test
specifically detects
antibodies against IB OX and IB D1466. No cross-reactivity was observed,
whereas no
distinction can be made between antibodies against IB OX and IB D1466 using
ELISA.
[0088] The data in Table 7 also show that after challenge there is a very
clear drop in the egg
production by the virulent I B OX challenge virus in the chickens which had
not been vaccinated.
Vaccination with live vaccines only, inactivated vaccine only or both results
in protective
immunity against an egg drop caused by IB OX challenge virus.
19
Date Recue/Date Received 2022-09-23
Table 7. Mean antibody titers to IB, 7 weeks after priming with live vaccines
(D98) and 7 weeks after
administration of inactivated vaccine (D147) and protection against egg drop
by after IB Q,X or IB D1466
challenges.
Mean arithmetic IS EL1SA antibody titer Mean SNT antibody Egg drops by
Vaccines IB QX or
D98 D147 titers D147***
Gr, 15D1466
I
Inacti; Titer Respon- Respon-
Live* Titer IS D1466 IS QX
vated
a7e, -------------------------
1 A
High
+ 5355A 40/401 18620A
dose (20/201 --- (10, 10.75 (11,
10,9, 8) 12, 10, 10) .3.9% QX
Low A ( (
5235A8 40/401 155328 (20/20)1 9258 9 7544 ' = ' ' -10'
2 + dose 10, 9, 8) 9, 10, 10) 2.5% QX
, , ,
3 + None 41618 40/401 872( (2/20)2 45 (4 4
47.758 (10, 8,
I 4) 67) -3,2% QX
I
A , ,
4 - High 22A 0/401 10520' (20/20)1 93 8,9)
(9, 12, 8.25 (6 8
4
dose 9,10)
-0.8% QX
Low 95A (10,
27A 0/401 8850A (20/20)1 8.75A (9,
- dose 12, 9,8) 11, 9, 8) 1.8% QY
6 - None 1 36A 11401 123' (1/20)2 4.258 (5,
4, 4.255 (4, 4,
5) -24.0% QX
High 20/201 9'754 (9,9, 11.54 (11,
7 + 146528
dose 10, 11) 11, 12, 12) 01466
Low (8,9, le (8, 10,
8 + 16457A 20/201 94
dose 10,9) 11, 11) 13.8% D1466
1
9 +None 11391 20/201 4-58 (4, 4, 75 (7,
7, 8,
5, 5) 6)
I 0.8% D1466
High 1
9552A 20/201 "A (8, 8,19A (8,9,
10,
-
dose 10, 8) 9) 0% 01466
Low
11 - 7762A 20/201 8754 (7' 9'834 (8'
8' 9'
dose 10, 9) 9) 2.3% D1466
12 - None 593 0/202 4.2e (4, 5, 4.258
(4, 4,
1
4,4) 5,4)
i 1 -8.3% 01466
'High dose: 10" Ms, IB QX and 106 8 El Do IB 01466, low dose: 16" ElDso IB OX
and 106.2E105D
18 D1466; VP TC1D50 TRT per dose at 112 days of age.
*POULVAC (B Primer in a single dose at 10 weeks of age and POULVAC IB QX in
a single dose
at 12 weeks of age.
**Different letters in each cell indicate that the difference in mean titer is
significant (P<0.05)
between each block of 3 groups.
*** IB QX and IB 01466 challenge administered at 147 days of age. The cut-off
for a positive
response was >5.
Date Recue/Date Received 2022-09-23
[00891 Further, it was previously thought that an inactivated IB OX antigen is
hardly capable to
Induce antibody titers in chickens after vaccination, unlike non-QX strains of
IB. For example,
currently marketed products containing antigens from other, non-QX, strains of
infectious
bronchitis (e.g., IB M41, or IB D274, or IB D1466) are adjuvanted with oil
emulsion without CpG
and yet elicit sufficient protection. In contrast, as demonstrated in Table 8,
oil emulsion
without CpG is insufficient to elicit neutralizing antibodies, while addition
of CpG results in a
robust antibody response.
Table 8. Antibody responses in 4-week old SPF chickens against the single
inactivated IB QX
antigens in a water-in-oil emulsion containing CpG
IB QX "log I nactivant CpG Serological test
.... at .... days after vaccination
strain ElDso per per ELISA at 35 ELISA at 49 ELISA at 85 I SN test
at 35
dose dose
11148 8.0 Formol 2.477 2.928 3.573 I 0.0
L1148 8.0 Formol 5 pg 3.460 3.924 4.047 5.0
L1148 8.0 BPL 2.179 2.444 2.861 I 3.0
L1148 8.0 BPL 5 pg 3.203 3.809 3.939 4.4
11148 7.2 Formol 1.395 0.976 2.314 0.8
L1148 7.2 BPL 1.940 2.185 3.124 0.0
1449-2 7.2 Formol 1628 2.994 3.397 3.0
1449-2 7.2 BPL 2.531 2.769 3.439 I 3.7
1449-2 7.2 BPL 5 tvg 2.774 3.191 3.621 I 4.3
None Placebo 1.793 0.000 1.191 I 0.0
[00901 At the same time, as noted above, known vaccine strains of 18 viruses
have proven
insufficient to protect against infectious bronchitis caused by I B-OX and 1B-
QX-Iike viruses. See
W02010017440. Surprisingly, the vaccines of the instant invention elicited a
clear antibody
response against the inactivated IB QX antigens.
Example 5. Vaccine against Infectious Bronchitis, Newcastle disease, TRT,
Infectious Bursai
Disease, and Reovirus
[00911 Mixed sex newborn SPF Leghorn chickens were used in this experiment.
Chickens were
fed standard diet with water ad libitum.
[00921 On day 0, the birds were vaccinated against Infectious Bronchitis with
a vaccine
containing Massachusetts 1 strain via ocular administration. On day 28 of the
experiment, the
birds were administered POULVAC. REO and POULVAC. TRT vaccines at dosages
21
Date Recue/Date Received 2022-09-23
recommended by the manufacturer into the birds' wings and eyes, respectively.
On day 49 of
the experiment, the birds were administered the experimental vaccines. Groups
101, T02,104,
and105 had 32 birds per group. Groups103,106, and T07 had 13 birds per group.
Table 9. Experimental vaccine compositions
Group Antigen component Adjuvant
101 IB (1063 EID (egg infectious dose)5o), Reo 1733 and W/O emulsion
(Mineral oil -49.9% v/v,
Reo2408 (10" TCIDso total), IBD Lukert (1071 emulsifiers (1WEEN=80 and
ARLACEL=
TCIDso), IBD 28-1 (10236 TCIDso) Newcastle (10" total ¨9.1% v/v) + 10 pg CpG
(SEQ ID
ElDso), TRT (1064 TCID60) NO: 8, 65% purity)
T02 IB (1063 ElDso), Reo 1733 and Reo2408 (1063 TCIDso As in 101
total), IBD Luken (1e TCIDs0), IBD 28-1 (10236
TCID50) Newcastle (10" EID50), TRT (106=46-1CID)
103 Negative control (no antigens) W/O emulsion as in 101 ¨ no CpG
T04 As in TO1 W/O emulsion as in 101 ¨ no CpG
105 As In 102 W/0 emulsion as In 101 ¨ no CpG
T06 MATERNAVAC DUO ¨1BDV + Reo Commercial Product
107 MSD-Nobilis (reference TRT) (18, Newcastle, IBDV, Commercial product
TRT)
Commercial name of MSD vaccine: NobilieRT+IBmulti+G+ND
[00931 All antigens used in 101, T02, T04, and TOS were inactivated in
formaldehyde.
[00941 Groups T01-T05 received a 0.5 ml intramuscular injection in the breast
area. Groups
TOG and 107 were treated according to the manufacturers' protocols.
[00951 Blood was taken from the birds on days 70 and 77 for serology analysis.
The analysis
was performed by serum neutralization test (IB, IBDV, Reo), HAI test
(Newcastle), and (LISA
(TRT). Serology data for 101, T02, T04 and T05 was analyzed using general
linear mixed model
with repeated measures. Appropriate log transformation was applied. Model
included fixed
effects of treatment, time point and treatment by time point interaction and
random effects of
block and animal within block and treatment (animal term).
[00961 (Back-transformed) least square means and 90% confidence intervals were
reported
along with range of the raw data. If the main effect of treatment or the
treatment by time
interaction was significant (P 0.10) then comparisons between all treatment
groups at each
time point were conducted and reported. Treatment groups 103, 106 and T07 were
summarized with geometric means, standard errors, and ranges.
[00971 The results are provided in Table 10.
22
Date Recue/Date Received 2022-09-23
Table 10. Antibody titer, back transformed geometric means
Bronchitis Newcastle I IBD Reo TRT TRT"
conversion,
D70 D77 D70 D77 070 D77 D70 D77 070 077 D70 D77
TO1 991 83' 89' 99' 4401" 3701b 484' 4ab
90.6 93.7 3684' 5598b
102 923 768 88' 1098 6499" 9190" 641' 5058 96.8 100 61558 79718
103 10 9 0 0 0 0 1 1 - - 0 0
104 160' 3.44' 23b 294 528` 1367' 222b 258/x 40.6 46.8 68' 1234
TOS 175' 102' 21b 27b 970b 2201bc 168b 208' 62.5 62.5 342' 445'
106 13 16 0 0 3527 7845 713 712 - .. - .. 0
.. 0
107 3719 2069 243 460 3005 7437 0.5 0.5 - - 24 239
Statistical analysis was done comparing the titers elicited by Treatments T01,
T02, T04 and T05.
Different letters indicate significant difference (p50.1).
TRT* indicates that the titer was obtained using ELISA. All other results were
obtained using by
serum neutralization test (113, IBDV, Reo) or HAI test (Newcastle)
[00981 These results demonstrate that addition of CpG to W/O emulsion resulted
in almost 3-
fold increased immune response to IBDV. Looking at the results from a
different perspective,
these results demonstrate that decrease of IBD Lukert dose from 108TCID50 to
107'5TCID50
(about three-fold reduction) and addition of CpG (compare TO1 and 105) to the
formulation
resulted in increased responses to IBD. Responses to Newcastle, reovirus, and
TRT were also
increased and the response to IS was not statistically decreased.
[00991 Further, the responses to all viruses resulted in protective titers
(protective titer for IB is
20, protective titer to Newcastle is 16, protective titer for IBD is 32,
protective titer for Reovirus
is 16). Efficiency of TRT vaccine is measured by seroconversion.
Seroconversion over 70%
indicated that the vaccine was effective.
[00100] In the experiments above, the formulations containing CpG (groups 101
and T02) were
both effective against TRT (over 90% seroconversion). In contrast, the
formulations lacking CpG
(groups 104 and TO5) were not effective against TRT (seroconversion of 62.5%
and below).
[00101] Group T06 was used as a positive control for 1BDV. As shown in Table
10, the titers
elicited by vaccine T02 were comparable to the titers elicited by the positive
control. Group
T07 was used as a positive control for TRT. As shown in Table 10, the
experimental vaccines
1-01 and T02 elicited higher TRT titers than 107.
23
Date Recue/Date Received 2022-09-23
100102] In sum, addition of CpG into the W/0 emulsion allowed creation of
pentavalent
vaccine effective against Bronchitis, Newcastle disease, TRT, Infectious
Bursa! Disease (IBD or
Gumbord and Reovirus. The formulations without CpG were not effective against
TRT. In
addition, the titers against Newcastle, Reovirus, and IBD were lower in the
formulations
without CpG than in formulations with CpG.
Example 6. Vaccine against infectious Bronchitis, Conga, Egg Drop Syndrome,
Newcastle
Disease, and TRT.
[00103] Mixed sex newborn SPF Leghorn chickens were used in this experiment.
Chickens
were fed standard diet with water ad libitum.
[00104] On day 0, the birds were vaccinated against Infectious Bronchitis with
a vaccine
containing Massachusetts 1 strain via ocular administration. On day 14 of the
experiment, the
birds were administered POULVACs TRT vaccines at dosages recommended by the
manufacturer intraocularly. On day 35 of the experiment, the experimental
vaccines were
administered via intramuscular injections.
[00105] Table 11 illustrates experimental and control vaccine compositions
used in these
experiments. Each of the group contained 56 birds.
Table 11. Experimental vaccine compositions
Group Antigen Adjuvant
101 None None (Saline)
102 POULVAC* MIX 6 (1BK (1.13" EID50), Coryza Proprietary
M, Coryza 221, Coryza S (total 106=88 EID50)),
EDS* (80.00 HA units), Newcastle (10845
EID50)
103 IBK (10" EID50), TRT (10" TC1050), Coryza W/O emulsion (Mineral oil -
51.6% v/v,
M, Coryza 221, Coryza S (total 10" ElDa emulsifiers (TWEEN*80 and ARLACELe
total
EDS (88.00 HA units), Newcastle 408'43E1050 -8.4% v/v)
T04 IBK (10610 EID50), TRT (10" TCID50), Coryza As in 103 + 10 lig CpG
(SEQ ID NO: 8, 6596
Coryza 221, Coryza S (total 10" ElDso), purity)
EDS (88.00 HA units), Newcastle (108.43E1D50)
TOS IBK (10" ElDso), TRT (108" TCIDso), Coryza As in T03
M, Coryza 221, Coryza S (total 10" ElDso),
EDS (88.00 HA units), Newcastle (108.43E1D50)
106 IBK (10" ElDso), TRT (10690 1CID50), Coryza As in T04
M, Coryza 221, Coryza S total 10"EID50),
EDS (88.00 HA units), Newcastle (108A3E1D5e)
*EDS refers to Egg-Drop Syndrome, IBK refers to Infectious Bronchitis
24
Date Recue/Date Received 2022-09-23
[00106] All antigens used in 101, T02, T04, and TOS were inactivated in
formaldehyde.
[00107] Blood was taken from the birds on days 56 and 70 for serology
analysis. Ten percent
two sided significance level was used in the analysis.
[00108] Serology data for T01, T03, T04, TO5 and T06 was analyzed using
general linear mixed
model with repeated measures. Appropriate log transformation was applied.
Model included
fixed effects of treatment, time point and treatment by time point interaction
and random
effects of block and animal within block and treatment (animal term).
[00109] (Back-transformed) least square means and 90% confidence intervals
were reported
along with range of the raw data. If the main effect of treatment or the
treatment by time
Interaction was significant (P s 0.10) then comparisons between all treatment
groups at each
time point were conducted and reported. Serology for T02 was summarized with
geometric
means, standard errors, and ranges.
[00110] The results for experimental groups (T03-T06) are summarized in Table
12.
Table 12. Antibody titers
GRP Bronchitis, SN EDS, HAI Coryza, SN Newcastle,
TRT, sero- TRT, ELISA
HAI conversion %
D56 D70 D56 D70 D56 D70 D56 D70 D56 D70 D56 D70
103 78 491 40 111 7 1 9 15 40 39 57 1527 b 1738`
14b 9 b 7b 21b lb 2 4b
104 288t 141t 71t 148 11 18 66t 80 86 95 31993 4708*
44' 25* 14* 30ab la 2' 7b 9a
TO5 70 44 40 103 5 8 21 37 34 45 1184c 1279d
12b 8b 7b 18b 1bc 1b 2c 4b
106 183t 94 91 216t 6 23 92 100 75 86 2964a 3641b
338 188 198 448 lb 38 108 118
Different letters indicate significant difference (pS0.1).
[00111] These results demonstrate that addition of CpG to W/O emulsion
resulted in 2-3-fold
increased Immune response to TRT measured by ELISA. Looking at the results
from the
seroconversion perspective, the groups treated with formulations without CpG
(treatments 103
and T05) did not demonstrate efficient TRT seroconversion response (57% or
less). In contrast,
groups treated with formulations TN and 106 both of which contained CpG
demonstrated
efficient seroconversion (75% and above). Even if the dose of TRT antigen was
decreased about
Date Recue/Date Received 2022-09-23
threefold, addition of CpG more than compensated for the lower antigen dose
(compare T04
and TO5).
1001121 Further, the responses to all viruses resulted in protective titers
(protective titer for
IS is 20, protective titer to Newcastle is 16, protective titer for Coryza is
5, protective titer for
EDS is 18). The SN titers or HAI fliers elicited by formulations T04 and T06
(containing CpG)
were generally about twice as great as the titers elicited by formulations 103
and T05 (without
CpG)
[00113]
[00114] Although the invention herein has been described with reference to
particular
embodiments, it is to be understood that these embodiments are merely
illustrative of the
principles and applications of the present invention. It is therefore to be
understood that
numerous modifications may be made to the illustrative embodiments and that
other
arrangements may be devised without departing from the spirit and scope of the
present
invention as defined by the following daims.
26
Date Recue/Date Received 2022-09-23
